Publications
- Kent A, Yee Mon KJ, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI, Blander JM. A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis. Nat Immunol. 2025 Jan;26(1):53-67. PubMed PMID: 39747433
- Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon CM, Gutman J, Pollyea DA, Amaya ML. Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. Leuk Lymphoma. 2025 Aug;66(8):1543-1545. PubMed PMID: 40080662
- Gilbert JS, Connor M, Bosma G, Zhang J, McMahon CM, Amaya ML, Gutman J, Schwartz M, Kent A, Abbott D, Pollyea DA. Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis. Am J Hematol. 2025 Nov;100(11):2140-2143. PubMed PMID: 40810378
- O'Brien C, Nursimulu N, Tyagi A, Culp-Hill R, Arruda A, Murphy T, Minden MD, Kent A, Stevens B, Pollyea DA, Hope K, Kumar S, Reisz JA, D'Alessandro A, Jones CL. Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia. Blood. 2025 Nov 20;146(21):2589-2596. PubMed PMID: 40857673
- Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda DM, Padron E, Sweet K, Sallman DA, Lancet J, Carraway HE, Watts J, Zeidan A, Pollyea DA, Komrokji RS. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (=?70?Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. Am J Hematol. 2025 Oct;100(10):1920-1923. PubMed PMID: 40772639
- Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M. Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia. Haematologica. 2025 Sep 11. [Epub ahead of print] PubMed PMID: 40931864
- Pollyea DA, Stevens BM, Abbott D, Amaya M, Gutman JA, Kent A, McMahon C, Schwartz M, Smith C, Dell-Martin J, Sohalski C, Ellis A, Haag M, Schowinsky J, Pan Z, Patel SB, Ransom M, Gillen A, Jordan CT, Pietras EM. Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial. EClinicalMedicine. 2025 Nov;89:103546. PubMed PMID: 41140451
- Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2024 Aug 17. [Epub ahead of print] PubMed PMID: 39154914
- Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, Pollyea DA, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024 Dec;65(14):2228-2230. PubMed PMID: 39229898
Practice Locations
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus12605 E. 16th Ave
Aurora, CO 80045
720-848-0000